177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

Inclusion Criteria: * Histological or cytological diagnosis of neoplasia (not mandatory for meningioma) * GEPNETs grade 3 or aggressive grade 2 tumours with a poor prognosis and a Ki67 \> 15% OR neuroendocrine tumours NOS after standard therapy OR thymomas/tumours of other origin after standard therapy OR meningiomas after standard therapy not suitable for surgery or radiotherapy * Evidence of regional or distant metastases or localised disease not accessible for complete resection * Measurable disease according to RECIST 1.1 * Evidence of somatostatin receptor positive disease detected by 68Ga-DOTA-TATE/TOC PET * Progressive disease during the last 14 months based on CT or new lesions detected by 68Ga-DOTA-TATE PET. * Performance status ECOG 0 - 1 * Life expectancy \> 6 months * Age \>18 years, no upper age limit. * Neutrophil count \>1,5 x 109/L * Platelet count \>100 x 109/L * Normal liver function regarding transaminases, PK and albumin. A raised bilirubin which can be considered an isolated effect of liver metastases is not a contraindication as long as the levels remain \<1.5 x ULN. * GFR \> 50 ml/min * Written informed consent from patients * Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women \<50 years of age would be consider…